Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Adult Neuroplasticity Restored by Astrocyte Protein CCN1 in Mouse Model

Neural circuits are refined by experience with higher plasticity at younger ages. Non-neuronal brain cells, known as astrocytes, were previously seen as passive support cells, but recent research has shown that they play an important role in shaping brain circ

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Neural circuits are refined by experience with higher plasticity at younger ages. Non-neuronal brain cells, known as astrocytes, were previously seen as passive support cells, but recent research has shown that they play an important role in shaping brain circuitry. How astrocytes in the brain maintain these differing plasticity levels with age, and whether they stabilize the properties of sensory circuits in adulthood, has remained unclear.

In a new study published in Nature titled, “Astrocyte CCN1 stabilizes neural circuits in the adult brain,” researchers from the Salk Institute have identified the astrocyte secreted protein, CCN1, as key for stabilizing brain circuits in adulthood, offering a new therapeutic target for neurological diseases, such as Alzheimer’s disease, depression, or post-traumatic stress disorder (PTSD).

“This study establishes the crucial role of astrocytes in actively stabilizing the connectivity of neuronal circuits,” said corresponding author Nicola Allen, PhD, professor and co-director of the NOMIS Foundation-funded Neuroimmunology Initiative at Salk. “Our findings demonstrate how the stability of sensory circuits is actively maintained in the adult brain. The discovery of CCN1 as a critical regulator of neuroplasticity could now inform the development of new therapeutics for brain injury and stroke, which has already been associated with CCN1 upregulation.”

Mammalian sensory circuits typically have higher plasticity at younger ages, a period of circuit refinement, and increased stability and reduced plasticity in adulthood. While stability in adulthood is necessary to maintain functional neuronal connectivity, the window for circuit plasticity can be re-opened by digesting the extracellular matrix with enzymes or by transplanting juvenile inhibitory neurons or astrocytes.

To determine the role of astrocytes in plasticity and circuit stability, the authors focused on the mouse visual cortex. Combining a transcriptomic approach with ex vivo electrophysiology and in vivo imaging, results showed that increase in CCN1 expression led to higher cellular maturation in both inhibitory neurons and oligodendrocytes, which dampened the circuits’ neuroplasticity. Conversely, knocking out astrocyte CCN1 in adults destabilized binocular circuits and reduced myelination.

Manipulating CCN1 levels could allow control of plasticity to recover or rebuild lost circuits after injury or trauma. To support this goal, CCN1 is known to bind to many extracellular components of many cell types, including excitatory and inhibitory neurons, oligodendrocytes, and microglia. By binding to important integrin proteins on the cell surface, CCN1 can coordinate the maturation of multiple cell types to reduce the plasticity of the adult brain.

“Maintaining stable circuits is important for proper brain function, but the consequence is that neural plasticity and remodeling are repressed in the adult brain,” said first author Laura Sancho, PhD, a postdoctoral researcher in Allen’s lab. “We wanted to find out if and how astrocytes participate in this critical maintenance, and we found they are in fact essential.”

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
02How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →